Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1713657 | 0.92 | ALDH1A1 (0.48) | ALDH1A1NQO2CYP1A1CYP1B1PTGS2 | |
| SCHEMBL775781 | 0.86 | CA1 (0.37) | CXCR2 | |
| SCHEMBL509273 | 0.85 | ALDH1A1 (0.41) | ALDH1A1NQO2CYP1A1CYP1B1FFAR4 | |
| SCHEMBL7367391 | 0.84 | ADORA2A (0.44) | ALDH1A1CYP1A1CYP1B1FFAR4SLC22A12 | |
| SCHEMBL309328 | 0.82 | ALDH1A1 (0.38) | ALDH1A1CYP1A1CYP1B1CXCR2AKR1C3 | |
| SCHEMBL926505 | 0.82 | CA2 (0.41) | CXCR2 | |
| SCHEMBL10204404 | 0.81 | EPAS1 (0.37) | FFAR4PTGS2CXCR2 | |
| SCHEMBL9957670 | 0.81 | ALDH1A1 (0.44) | ALDH1A1NQO2CYP1A1CYP1B1FFAR4 | |
| SCHEMBL4730537 | 0.81 | CYP1A1 (0.47) | ALDH1A1NQO2CYP1A1CYP1B1PTGS2 | |
| SCHEMBL4174925 | 0.81 | EPAS1 (0.39) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858857-B1 | AZABICYCLOALKANE DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | LILLY CO ELI (US) | 2010-12-08 | — | — | EP | disclosed |
| US-7645761-B2 | Indoline derivatives | WYETH (US) | 2010-01-12 | — | — | US | disclosed |
| US-20080261999-A1 | Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-23 | — | — | US | disclosed |
| US-20080261999-A1 | Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-23 | — | — | US | disclosed |
| US-20080261999-A1 | Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-23 | — | — | US | disclosed |
| US-20070259944-A1 | Indoline derivatives | WYETH (US) | 2007-11-08 | — | — | US | disclosed |
| US-7253203-B2 | Indoline derivatives | WYETH (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1175398-B1 | INDOLINE DERIVATIVES AS PROGESTERONE ANTAGONISTS | WYETH CORP (US) | 2007-07-11 | — | — | EP | disclosed |
| US-7084168-B2 | Indoline derivatives | WYETH (US) | 2006-08-01 | — | — | US | disclosed |
| US-20060160882-A1 | Indoline derivatives | WYETH (US) | 2006-07-20 | — | — | US | disclosed |
| US-6608068-B2 | Substituted indoline derivative compounds which are antagonists of the progesterone receptor; contraceptives; antineoplastic agents | WYETH | 2003-08-19 | — | — | US | disclosed |
| US-6544970-B2 | Administering in a first phase of a progestational agent (levonorgestrel or ethinylestradiol) and in a second phase an antiprogestin that is an indolinone derivative, especially a 3-spiroalkylene derivative | WYETH | 2003-04-08 | — | — | US | disclosed |
| US-20030050288-A1 | Cyclic regimens utilizing indoline derivatives | WYETH | 2003-03-13 | — | — | US | disclosed |
| US-6462032-B1 | Cyclic regimens utilizing indoline derivatives | WYETH | 2002-10-08 | — | — | US | disclosed |
| US-20020086874-A1 | Indoline derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-07-04 | — | — | US | disclosed |
| US-6391907-B1 | ANTICANCER AGENTS; CONTRACEPTIVES | AMERICAN HOME PRODUCTS CORPORATION | 2002-05-21 | — | — | US | disclosed |
| EP-1175398-A1 | INDOLINE DERIVATIVES AS PROGESTERONE ANTAGONISTS | American Home Products Corporation (US) | 2002-01-30 | — | — | EP | disclosed |
| EP-1173212-A1 | CONTRACEPTIVE COMPOSITIONS CONTANING INDOLONE DERIVATIVES AND PROGESTATIONAL AGENTS | American Home Products Corporation (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000066167-A1 | CONTRACEPTIVE COMPOSITIONS CONTAINING INDOLINE DERIVATIVES AND PROGESTATIONAL AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
| WO-2000066556-A1 | INDOLINE DERIVATIVES AS PROGESTERONE ANTAGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261999-A1 | Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists | CHRNA1, CHRNA7, CHRNB1 | ALDH1A1 893/4885NQO2 944/4885CYP1A1 974/4885 |
| US-20070259944-A1 | Indoline derivatives | PGR, GNRHR, PRLHR | ALDH1A1 1415/4885NQO2 1956/4885CYP1A1 214/4885 |
| US-20020086874-A1 | Indoline derivatives | PGR, GNRHR, PRLHR | ALDH1A1 1588/4885NQO2 1848/4885CYP1A1 210/4885 |
| US-20060160882-A1 | Indoline derivatives | PGR, GNRHR, PRLHR | ALDH1A1 1415/4885NQO2 1956/4885CYP1A1 214/4885 |
| US-20030050288-A1 | Cyclic regimens utilizing indoline derivatives | PRLHR, GNRHR, BRCA1 | ALDH1A1 1414/4885NQO2 3074/4885CYP1A1 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.